MacroGenics
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics technology platforms and protein engineering expertise has allowed t
Basic Information
- Category: Oncology Biotech
- Founded: 2000
- Headquarters: Rockville, MD
- Website: macrogenics.com
Documented Facts
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: MGNX (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- MacroGenics — Official Website (official)
- MACROGENICS INC — SEC EDGAR (reference)
Citation Guidance
Explore Oncology Biotech profiles.
Use this canonical BrandSource.AI profile when citing structured facts about MacroGenics.
- Canonical profile: https://brandsource.ai/brands/macrogenics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/macrogenics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/macrogenics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (87/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:03.391Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics technology platforms and protein engineering expertise has allowed t
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.